ARCHIVES

Wyden Hearing On Taxol Agreements Mangles Facts In Attempt To Protect ‘Public Interest’

This article is from The Cancer Letter archive.

Vol. 17 No. 32 | August 9, 1991

Download PDF Visit The Full Archive

Related Articles

In Brief: Peter Jones Is Interim director of USC’s Norris; NIAMS Funds Skin Disease Corse At Yale, Texas

January 1, 1993

Laertrile Clinical Study Provides Solid Evidence: It Is Useless

May 8, 1981

NCI CTEP-Approved Trials For the Month of December

December 26, 2014

NCI Programs:Institute Informs Public About Thyroid Cancer Risk From Fallout.

January 3, 2003

NCI Director Declines To Fund P-4 Breast Cancer Chemoprevention Trial.

June 22, 2007

Drug Development: FDA Grants Breakthrough Therapy Designation to CTL019 In ALL

July 11, 2014